SynthesisMedical oncology (Northwood, London, England)2014
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
Synthesis in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer.Frontiers in oncology · 2023Pooled it
- A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer.British journal of cancer · 2020Pooled it
- Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.British journal of clinical pharmacology · 2018Pooled it
- TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.British journal of cancer · 2016Pooled it
- Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer: A Bayesian network meta-analysis.Cancer innovation · 2024Article
- Article
- Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups.Frontiers in oncology · 2022Review
- A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.JNCI cancer spectrum · 2019Review
- Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.Journal of translational medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progression-free survival (PFS) has not yet been established as a surrogate endpoint for overall survival (OS) in metastatic breast cancer (MBC). In particular, surrogacy has not been investigated with modern molecular agents. Randomized phase III trials for MBC were identified using a PubMed and EMBASE search. Correlations between PFS/time to progression (TTP), post-progression survival (PPS), response rate (RR) and OS were evaluated through a linear regression analysis. We also evaluated the potential of PFS to serve as a surrogate for OS in first-line trials exploring new drugs. Twenty trials with a total of 32 treatment arms and 10,138 patients were included. Spearman rank correlation coefficients (r s) between median PFS/TTP, RR and PPS with OS were 0.81 (95 % CI 0.58-0.92), 0.61 (95 % CI 0.59-0.63) and 0.73 (95 % CI 0.71-0.74). The correlation coefficient between hazard ratios in PFS/TTP and OS (HRPFS/TTP/HROS) was 0.73 (95 % CI 0.719-0.738; p < 0.00001); the slope of the regression line was 0.56 ± 0.0034, indicating that an agent producing a 10 % risk reduction for PFS will provide a 5.6 ± 0.34 % risk reduction for OS. In particular, the HRPFS/TTP/HROS correlation is stronger in an HER2-positive setting versus HER2-negative (r s = 0.91 vs. 0.67; p for difference <0.0001). These results suggest that improvements in PFS/TTP in MBC strongly correlate with improvements in OS with molecular agents, especially anti-HER2 therapeutics. Further analyses at patient-level data are required to confirm the surrogacy of PFS for OS with new agents.
Indexed as
Identifiers
24271313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.